Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | NA |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | lung adenocarcinoma tissues ,cell lines (Calu-3, NCI-H1975, A549,NCI-H23) |
| Expression Pattern | up-regulated |
| Function Description | The results indicated that highly expressed H19 and poorly expressed miR-29b-3p could serve as predictors for the poor prognosis of lung adenocarcinoma patients. |
| Pubmed ID | 30747209 |
| Year | 2019 |
| Title | lncRNA H19 promotes viability and epithelial-mesenchymal transition of lung adenocarcinoma cells by targeting miR-29b-3p and modifying STAT3. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |